Your browser doesn't support javascript.
loading
The impact of hydrocodone rescheduling on utilization, abuse, misuse, and overdose deaths.
Karami, Sara; Ajao, Adebola; Wong, Jennie; Zhang, Di; Meyer, Tamra; Ding, Yulan; Secora, Alex; Major, Jacqueline M; Gill, Rajdeep; Chai, Grace P; Zhao, Yueqin; McAninch, Jana.
Afiliación
  • Karami S; Division of Epidemiology II (DEPI-II), Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • Ajao A; Division of Epidemiology II (DEPI-II), Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • Wong J; Division of Epidemiology II (DEPI-II), Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • Zhang D; Division of Epidemiology II (DEPI-II), Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • Meyer T; Division of Epidemiology II (DEPI-II), Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • Ding Y; Division of Epidemiology II (DEPI-II), Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • Secora A; Division of Epidemiology II (DEPI-II), Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • Major JM; Associate Director, Epidemiology, IQVIA Government Solutions, Virginia, USA.
  • Gill R; Division of Epidemiology II (DEPI-II), Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • Chai GP; Division of Epidemiology II (DEPI-II), Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • Zhao Y; Division of Epidemiology II (DEPI-II), Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • McAninch J; Division of Epidemiology II (DEPI-II), Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
Pharmacoepidemiol Drug Saf ; 32(7): 735-751, 2023 Jul.
Article en En | MEDLINE | ID: mdl-36779261
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Sobredosis de Droga / Hidrocodona Idioma: En Revista: Pharmacoepidemiol Drug Saf Asunto de la revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Sobredosis de Droga / Hidrocodona Idioma: En Revista: Pharmacoepidemiol Drug Saf Asunto de la revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article